{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T07:36:30Z","timestamp":1774596990787,"version":"3.50.1"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2508106"],"award-info":[{"award-number":["2023YFC2508106"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073429, 82273510, 82430101, 82173405, 82473517"],"award-info":[{"award-number":["82073429, 82273510, 82430101, 82173405, 82473517"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Psoriasis is a T cell-mediated inflammatory skin disease, and biologics have demonstrated promising efficacy. However, some patients remain dissatisfied with early therapeutic outcomes. Immune checkpoint molecules on T cells play critical roles in psoriasis pathogenesis, yet their impact on therapeutic response remains unclear. This study aimed to identify predictive markers for the early therapeutic efficacy of ixekizumab in psoriasis patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-two patients with plaque psoriasis were enrolled in this study. All participants received ixekizumab for 24 weeks. Peripheral blood was collected at multiple time points, and flow cytometry was used to assess T cell subsets and the expression of immune checkpoint molecules, including T cell immunoreceptor with Ig and ITIM domains (TIGIT), lymphocyte activating gene 3 (LAG-3), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), B and T lymphocyte-associated protein, endothelial protein C receptor (PROCR), podoplanin (PDPN), programmed cell death 1 (PD-1), and B7-Homolog 6 (B7-H6).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ixekizumab treatment reduced the proportion of T helper 17 (Th17) cells and IL-17-secreting CD8\n                      <jats:sup>+<\/jats:sup>\n                      T (Tc17) cells and downregulated B7-H6 and LAG-3 expression on CD4\n                      <jats:sup>+<\/jats:sup>\n                      T cells by week 24. Similarly, LAG-3 expression on CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells decreased. Notably, baseline levels of Th17 and Tc17 cells, as well as LAG-3 expression on CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, were higher in non-early responders than in early responders.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Ixekizumab treatment may restore immune dysregulation in psoriasis patients. Baseline proportions of Th17 and Tc17 cells, along with LAG-3 expression on CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, may serve as candidate exploratory markers for the early therapeutic efficacy of ixekizumab.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1653033","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:39:52Z","timestamp":1774593592000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Baseline Th17\/Tc17 and LAG-3 levels serve as candidate exploratory markers for early ixekizumab response in psoriasis"],"prefix":"10.3389","volume":"17","author":[{"given":"Nan","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxiong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangluyi","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suyang","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Surgery, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Dermatologic Surgery, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Gu","sequence":"additional","affiliation":[{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Department of Dermatology, Shanghai Tenth People\u2019s Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Gong","sequence":"additional","affiliation":[{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Department of Dermatology, Shanghai Tenth People\u2019s Hospital, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuling","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine","place":["Shanghai, China"]},{"name":"Institute of Psoriasis, Tongji University School of Medicine","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.116.026859","article-title":"Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study","volume":"136","author":"Lerman","year":"2017","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.2907","article-title":"Comparison of coronary artery calcium scores between patients with psoriasis and type 2 diabetes","volume":"152","author":"Mansouri","year":"2016","journal-title":"JAMA Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"B6","article-title":"New insights into the pathogenesis of cutaneous autoimmune disorders","volume":"26","author":"Chiricozzi","year":"2012","journal-title":"J Biol Regul Homeost Agents"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19325","article-title":"Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis","volume":"183","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac089","article-title":"Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase iii\/iiib trials","volume":"188","author":"Kokolakis","year":"2023","journal-title":"Br J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase iii randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase iii trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaad.2018.04.012","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)","volume":"79","author":"Gottlieb","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (RESURFACE 1 and RESURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase iii, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase iii, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (ULTIMMA-1 and ULTIMMA-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19132","article-title":"Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase iii trial (AMAGINE-1)","volume":"183","author":"Papp","year":"2020","journal-title":"Br J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18851","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial","volume":"182","author":"Blauvelt","year":"2020","journal-title":"Br J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2016.64","article-title":"New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis","volume":"18","author":"Prieto-P\u00e9rez","year":"2018","journal-title":"Pharmacogenomics J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2217\/pgs-2017-0143","article-title":"Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis","volume":"19","author":"Ovejero-Benito","year":"2018","journal-title":"Pharmacogenomics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/tpj.2016.70","article-title":"Il17ra gene variants and anti-TNF response among psoriasis patients","volume":"18","author":"Batalla","year":"2018","journal-title":"Pharmacogenomics J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2015.11.008","article-title":"Cdkal1 gene variants affect the anti-TNF response among psoriasis patients","volume":"29","author":"Coto-Segura","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"B28","article-title":"The potential of IL-12 in predicting clinical response to etanercept treatment in patients with psoriasis","volume":"9","author":"Lu","year":"2016","journal-title":"Int J Clin Exp Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/tpj.2017.31","article-title":"Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis","volume":"18","author":"Loft","year":"2018","journal-title":"Pharmacogenomics J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.11.038","article-title":"HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis","volume":"143","author":"Dand","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/s41467-021-25066-9","article-title":"Enhanced NF-\u03baB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis","volume":"12","author":"Andres-Ejarque","year":"2021","journal-title":"Nat Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1403a166","article-title":"Effectiveness of ixekizumab in elderly patients for the treatment of moderate-to-severe psoriasis: results from a multicenter, retrospective real-life study in the Lazio region","volume":"14","author":"Dattola","year":"2024","journal-title":"Dermatol Pract Concept"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0206-z","article-title":"Induction and transcriptional regulation of the co-inhibitory gene module in T cells","volume":"558","author":"Chihara","year":"2018","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adj7970","article-title":"The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance","volume":"9","author":"Kilian","year":"2024","journal-title":"Sci Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-22392-6_8","article-title":"The potential role of inhibitory receptors in the treatment of psoriasis","volume":"75","author":"Shah","year":"2017","journal-title":"Bull Hosp Jt Dis (2013)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112663","article-title":"Novel insights into immune checkpoints in psoriasis and atopic dermatitis: from expression and function to treatments","volume":"139","author":"Liu","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200323382","article-title":"The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells","volume":"33","author":"Workman","year":"2003","journal-title":"Eur J Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.9.5450","article-title":"Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo","volume":"172","author":"Workman","year":"2004","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aah4569","article-title":"LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes","volume":"2","author":"Zhang","year":"2017","journal-title":"Sci Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.05.021","article-title":"Proportion of CD4(+)CD49b(+)LAG-3(+) type 1 regulatory T cells in the blood of psoriasis patients inversely correlates with psoriasis area and severity index","volume":"138","author":"Kim","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2091","article-title":"Depletion of LAG-3(+) T cells translated to pharmacology and improvement in psoriasis disease activity: a phase I randomized study of MAb GSK2831781","volume":"109","author":"Ellis","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13414","article-title":"TIGIT expression levels on CD4+ T cells are correlated with disease severity in patients with psoriasis","volume":"43","author":"Wang","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107722","article-title":"Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis","volume":"96","author":"Yu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.36849\/jdd.6063","article-title":"Early response is associated with stable long-term response in psoriasis patients receiving ixekizumab or ustekinumab","volume":"21","author":"Augustin","year":"2022","journal-title":"J Drugs Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12610","article-title":"Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis","volume":"169","author":"Zhu","year":"2013","journal-title":"Br J Dermatol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"AB47","DOI":"10.1016\/j.jaad.2022.06.223","article-title":"33566 Early response with ixekizumab predicts long-term outcomes up to 5 years in psoriasis by unsupervised and supervised machine learning analyses","volume":"87","author":"Egeberg","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090681","article-title":"The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans","volume":"206","author":"Brandt","year":"2009","journal-title":"J Exp Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2010.07.007","article-title":"CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions","volume":"71","author":"Laurent","year":"2010","journal-title":"Hum Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2017.11.007","article-title":"The expression of mCTLA-4 in skin lesion inversely correlates with the severity of psoriasis","volume":"89","author":"Liu","year":"2018","journal-title":"J Dermatol Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir165","article-title":"B and T lymphocyte attenuator down-regulation by HIV-1 depends on type I interferon and contributes to T-cell hyperactivation","volume":"203","author":"Zhang","year":"2011","journal-title":"J Infect Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0910528","article-title":"Regulation of inflammation, autoimmunity, and infection immunity by hvem-btla signaling","volume":"89","author":"Shui","year":"2011","journal-title":"J Leukoc Biol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab620","article-title":"The pivotal role of endothelial protein C receptor for antiphospholipid antibody-mediated pathologies","volume":"61","author":"Chu","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B53","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/cei.12830","article-title":"Role of podoplanin in the high interleukin-17a secretion resulting from interactions between activated lymphocytes and psoriatic skin-derived mesenchymal cells","volume":"186","author":"Noack","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92321","article-title":"Podoplanin is a negative regulator of Th17 inflammation","volume":"2","author":"Nylander","year":"2017","journal-title":"JCI Insight"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm057","article-title":"Pd-1 and pd-1 ligands: From discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5385102","article-title":"Suppressed programmed death 1 expression on cd4(+) and cd8(+) t cells in psoriatic patients","volume":"2017","author":"Bartosi\u0144ska","year":"2017","journal-title":"Mediators Inflammation"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2018.75609","article-title":"Decreased blood cd4+pd-1+ and cd8+pd-1+ t cells in psoriatic patients with and without arthritis","volume":"35","author":"Bartosi\u0144ska","year":"2018","journal-title":"Postepy Dermatol Alergol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2016.09.021","article-title":"Clinical efficacy and safety of ixekizumab for treatment of psoriasis","volume":"108","author":"Azevedo","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830250949","article-title":"Cd4\/major histocompatibility complex class ii interaction analyzed with cd4- and lymphocyte activation gene-3 (lag-3)-ig fusion proteins","volume":"25","author":"Huard","year":"1995","journal-title":"Eur J Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01152-y","article-title":"Type I interferon transcriptional network regulates expression of coinhibitory receptors in human t cells","volume":"23","author":"Sumida","year":"2022","journal-title":"Nat Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.Cir-20-0736","article-title":"Systemic immune dysfunction in cancer patients driven by il6 induction of lag3 in peripheral cd8+ t cells","volume":"10","author":"Somasundaram","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01619","article-title":"Cd4(+)cd25(+)lag3(+) t cells with a feature of th17 cells associated with systemic lupus erythematosus disease activity","volume":"10","author":"Kato","year":"2019","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.10.606","article-title":"Role of adam10\/17-mediated cleavage of lag3 in the impairment of immunosuppression in psoriasis","volume":"145","author":"Yu","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13407","article-title":"Tigit as an emerging immune checkpoint","volume":"200","author":"Harjunp\u00e4\u00e4","year":"2020","journal-title":"Clin Exp Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1653033\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:39:54Z","timestamp":1774593594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1653033\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":64,"alternative-id":["10.3389\/fimmu.2026.1653033"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1653033","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"article-number":"1653033"}}